Insight

Sabine D. Brookman-May: Excellent coverage on lymph-node-only metastatic urothelial cancer

Photo taken from Sabine D. Brookman-May/X

Jun 6, 2024, 06:52

Sabine D. Brookman-May: Excellent coverage on lymph-node-only metastatic urothelial cancer

Sabine D. Brookman-May, Professor of Urology at Munchen University, shared a post by UroToday.com on X, adding:

“Excellent coverage on lymph-node-only metastatic urothelial cancer as a distinct entity among complete responders to Nivo/GC.

Med OS in LN-only mUC: 46.3 (Nivo+GC) vs 24.9 months with GC (HR 0.58).”

Quoting UroToday.com’s post:

“Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from CheckMate 901. Presented by Matt Galsky.”

Read further
Sources: Sabine D. Brookman-May/X and UroToday.com/X

ASCO ASCO24 cancer CheckMate 901 gemcitabine-cisplatin lymph-node-only metastatic urothelial cancer Matt Galsky Nivo/GC nivolumab + gemcitabine-cisplatin OncoDaily Oncology Sabine D. Brookman-May urothelial cancer urothelial carcinoma

Side Effects of Radiotherapy: Risks and What to Know

Isabel Rubio has been elected as the President of the European Cancer Organisation for 2026-2027

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Special Coverage